Real‐world tolerance of sublingual immunotherapy for aeroallergens in severe allergic asthmatic children controlled on omalizumab
Pediatric Allergy and Immunology · 2026-11 · 37 (11)
DOI: 10.1111/pai.70523 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, online erschienen am 02.11.2026. Verfasst von François Maury und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Allergology, Armand Trousseau University Hospital, Groupe Hospitalier Universitaire, AP-HP Sorbonne-University, Paris, France. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Allergology, Armand Trousseau University Hospital, Groupe Hospitalier Universitaire, AP-HP Sorbonne-University, Paris, France.
ORCID-Profile: Mélisande Bourgoin-Heck, Stéphanie Wanin
Zitieren
APA
Maury, F., Dufrois, C., Lambert, N., Bourgoin-Heck, M., & Wanin, S. (2026). Real‐world tolerance of sublingual immunotherapy for aeroallergens in severe allergic asthmatic children controlled on omalizumab. Pediatric Allergy and Immunology, 37(11). https://doi.org/10.1111/pai.70523
Vancouver
Maury F, Dufrois C, Lambert N, Bourgoin-Heck M, Wanin S. Real‐world tolerance of sublingual immunotherapy for aeroallergens in severe allergic asthmatic children controlled on omalizumab. Pediatric Allergy and Immunology. 2026;37(11). doi:10.1111/pai.70523
BibTeX
@article{Maury2026,
author = {Maury, François and Dufrois, Caroline and Lambert, Nathalie and Bourgoin-Heck, Mélisande and Wanin, Stéphanie},
title = {Real‐world tolerance of sublingual immunotherapy for aeroallergens in severe allergic asthmatic children controlled on omalizumab},
journal = {Pediatric Allergy and Immunology},
year = {2026},
volume = {37},
number = {11},
doi = {10.1111/pai.70523}
}
EUVIMED